Strong net sales growth and positive EBIT – forecast for 2023 confirmed
|
EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Forecast Ad-hoc notification in accordance with Sec. 17 of the MAR Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed Lübeck, April 17, 2023 – Dräger's net sales in the first quarter of 2023 increased by 18.0 percent (net of currency effects) to around EUR 761 million, thus significantly surpassing the prior-year figure (3 months 2022: EUR 649.5 million). This was due in particular to the significant improvement in delivery capabilities, which enabled strong sales growth from the high order backlog. In addition, the significant increase in demand for ventilators in China had a positive impact on the sales development. In the medical division, net sales in the first quarter increased by 23.0 percent (net of currency effects) to around EUR 470 million (3 months 2022: EUR 385.2 million). In the safety division, net sales rose by 10.7 percent (net of currency effects) to around EUR 291 million (3 months 2022: EUR 264.3 million). Preliminary calculated earnings before interest and taxes (EBIT) improved to around EUR 29 million (3 months 2022: EUR -35.1 million) in line with the significant net sales growth. Gross margin increased to around 45 percent (3 months 2022: 42.2 percent), in particular due to the positive change in the product mix. Order intake in the first quarter of 2023 was down 1.9 percent year on year (net of currency effects), amounting to around EUR 804 million (3 months 2022: EUR 825.7 million). The medical division recorded a decrease of 7.6 percent (net of currency effects) to around EUR 465 million (3 months 2022: EUR 507.9 million), while the safety division reported an increase of 7.2 percent (net of currency effects) to around EUR 338 million (3 months 2022: EUR 317.8 million). Dräger confirms its forecast for the current fiscal year. Accordingly, the Company expects a return to growth and profitability with an increase in net sales of 7.0 to 11.0 percent (net of currency effects) and an EBIT margin of 0.0 to 3.0 percent. Full results for the first three months of the fiscal year will be published on April 28, 2023.
Drägerwerk AG & Co. KGaA
Investor Relations:
Corporate Communications:
Disclaimer End of Inside Information
17-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Drägerwerk AG & Co. KGaA |
| Moislinger Allee 53-55 | |
| 23558 Lübeck | |
| Germany | |
| Phone: | +49 (0)451 882-0 |
| Fax: | +49 (0)451 882-2080 |
| E-mail: | info@draeger.com |
| Internet: | www.draeger.com |
| ISIN: | DE0005550602, DE 000 555 063 6, DE 000 555 071 9 |
| WKN: | 555060, 555063 Vorzüge, 555071 Genussschein D |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart, Tradegate Exchange |
| EQS News ID: | 1609499 |
| End of Announcement | EQS News Service |
|
|
1609499 17-Apr-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.